Insider Buying: Savara Inc. (NASDAQ:SVRA) Director Buys 48,225 Shares of Stock

Savara Inc. (NASDAQ:SVRA - Get Free Report) Director Richard J. Hawkins bought 48,225 shares of Savara stock in a transaction dated Friday, June 20th. The stock was acquired at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the transaction, the director now directly owns 115,466 shares of the company's stock, valued at approximately $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Savara Trading Up 4.9%

Savara stock traded up $0.10 during midday trading on Monday, hitting $2.16. 855,181 shares of the stock were exchanged, compared to its average volume of 1,418,657. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $5.11. The stock has a market capitalization of $373.33 million, a price-to-earnings ratio of -4.50 and a beta of 0.32. The stock's 50-day simple moving average is $2.76 and its 200 day simple moving average is $2.83. The company has a current ratio of 14.91, a quick ratio of 14.91 and a debt-to-equity ratio of 0.20.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). On average, equities analysts anticipate that Savara Inc. will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cibc World Markets Corp acquired a new stake in shares of Savara during the fourth quarter valued at about $33,000. XTX Topco Ltd acquired a new stake in shares of Savara during the fourth quarter valued at about $34,000. Ameriprise Financial Inc. acquired a new stake in shares of Savara during the fourth quarter valued at about $37,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara during the fourth quarter valued at about $41,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Savara in the fourth quarter valued at approximately $48,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SVRA shares. Evercore ISI reduced their target price on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. HC Wainwright cut shares of Savara from a "buy" rating to a "neutral" rating and reduced their target price for the company from $6.00 to $2.00 in a research report on Thursday, May 29th. Wells Fargo & Company reduced their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Finally, Guggenheim reiterated a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.